LCTX — Lineage Cell Therapeutics Share Price
0.000.00%
Last trade - 00:00- $111.89m
- $62.84m
- $9.50m
- 31
- 23
- 15
- 11
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.43 | ||
| Price to Tang. Book | 5.29 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 11.78 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -21.64% | ||
| Return on Equity | -26.25% | ||
| Operating Margin | -226.11% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1.83 | 4.34 | 14.7 | 8.95 | 9.5 | 8.1 | 26.95 | 22% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological and ophthalmic conditions. The Company’s programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, it designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.
Directors
- Alfred Kingsley CHM (78)
- Brian Culley CEO (50)
- Kevin Cook CFO (50)
- Alexandra Hernandez FID
- Gary Hogge SVP (53)
- George Samuel GCN
- Dipti Amin IND (57)
- Deborah Andrews IND (63)
- Don Bailey IND (75)
- Neal Bradsher IND (56)
- Anula Jayasuriya IND (64)
- Michael Mulroy IND (55)
- Angus Russell IND (65)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 30th, 1990
- Public Since
- March 5th, 1992
- No. of Shareholders
- 351
- No. of Employees
- 70
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NYSE MKT
- Shares in Issue
- 228,356,290
- Address
- 2173 Salk Avenue, Suite 200, CARLSBAD, 92008
- Web
- https://lineagecell.com/
- Phone
- +1 5105213390
- Auditors
- WithumSmith Brown PC
Upcoming Events for LCTX
Lineage Cell Therapeutics Inc Annual Shareholders Meeting
Q2 2025 Lineage Cell Therapeutics Inc Earnings Release
Similar to LCTX
Actinium Pharmaceuticals
NYSE MKT
Aeon Biopharma
NYSE MKT
Armata Pharmaceuticals
NYSE MKT
Azitra
NYSE MKT
Biomx
NYSE MKT
FAQ
What is the Lineage Cell Therapeutics share price?
As of Today at 21:47 UTC, shares in Lineage Cell Therapeutics are trading at $0.49. This share price information is delayed by 15 minutes.
How has the Lineage Cell Therapeutics share price performed this year?
Shares in Lineage Cell Therapeutics last closed at $0.49 and the price had moved by -55.86% over the past 365 days. In terms of relative price strength the Lineage Cell Therapeutics share price has underperformed the S&P500 Index by -59.25% over the past year.
What are the analyst and broker recommendations for Lineage Cell Therapeutics?
The overall consensus recommendation for Lineage Cell Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Lineage Cell Therapeutics dividend yield?
Lineage Cell Therapeutics does not currently pay a dividend.
Does Lineage Cell Therapeutics pay a dividend?
Lineage Cell Therapeutics does not currently pay a dividend.
When does Lineage Cell Therapeutics next pay dividends?
Lineage Cell Therapeutics does not currently pay a dividend.
How do I buy Lineage Cell Therapeutics shares?
To buy shares in Lineage Cell Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Lineage Cell Therapeutics?
As of the previous close price of $0.49, shares in Lineage Cell Therapeutics had a market capitalisation of $111.89m.
Where are Lineage Cell Therapeutics shares listed?
Here are the trading details for Lineage Cell Therapeutics:
- Country of listing: United States
- Exchange: ASQ
- Ticker Symbol: LCTX
What kind of share is Lineage Cell Therapeutics?
Based on an overall assessment of its quality, value and momentum Lineage Cell Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Lineage Cell Therapeutics share price forecast for 2025?
The analyst consensus target price for shares in Lineage Cell Therapeutics is $3.92. That is 700% above the last closing price of $0.49.
Analysts covering Lineage Cell Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.09 for the next financial year.
Find out moreWhat is the trend in the Lineage Cell Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Lineage Cell Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -38.59%.
As of the last closing price of $0.49, shares in Lineage Cell Therapeutics were trading -31.85% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Lineage Cell Therapeutics PE Ratio?
The Lineage Cell Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.49.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Lineage Cell Therapeutics?
Lineage Cell Therapeutics' management team is headed by:
- Alfred Kingsley - CHM
- Brian Culley - CEO
- Kevin Cook - CFO
- Alexandra Hernandez - FID
- Gary Hogge - SVP
- George Samuel - GCN
- Dipti Amin - IND
- Deborah Andrews - IND
- Don Bailey - IND
- Neal Bradsher - IND
- Anula Jayasuriya - IND
- Michael Mulroy - IND
- Angus Russell - IND